Paraneoplastic syndromes of the neuromuscular junction: Therapeutic options in myasthenia gravis, Lambert-Eaton myasthenic syndrome, and neuromyotonia

Current Treatment Options in Neurology

Volumn 15, Issue 2, 2013, Pages 224-239

  Van Sonderen, Agnes ^a   Wirtz, Paul W ^a   Verschuuren, Jan J G M ^b   Titulaer, Maarten J ^b  

^a HAGA HOSPITAL   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

3,4 diaminopyridine; Immunotherapy; Isaacs syndrome; Lambert Eaton myasthenic syndrome; Myasthenia gravis; Neuromuscular junction; Neuromyotonia; Paraneoplastic syndromes; Pyridostigmine bromide; Therapy; Treatment

Indexed keywords

3,4 DIAMINOPYRIDINE; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PYRIDOSTIGMINE; RITUXIMAB; TACROLIMUS;

ACUTE KIDNEY FAILURE; ACUTE RESPIRATORY FAILURE; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANXIETY; ARTICLE; BONE MARROW SUPPRESSION; BRADYCARDIA; CHILL; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; CUSHINGOID SYNDROME; DIABETES MELLITUS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RESPONSE; DYSPNEA; EATON LAMBERT SYNDROME; EPIGASTRIC DISCOMFORT; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; HEADACHE; HEMATOMA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERSALIVATION; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPERTRICHOSIS; HYPOMAGNESEMIA; HYPOTENSION; INFECTION; INFECTION COMPLICATION; INSOMNIA; KIDNEY FAILURE; LEUKOPENIA; MACROCYTIC ANEMIA; MENTAL DISEASE; MOUTH ULCER; MYALGIA; MYASTHENIA GRAVIS; MYOKYMIA; MYOPATHY; NAUSEA; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; ORAL PARESTHESIA; OSTEOPOROSIS; PARESTHESIA; PLASMAPHERESIS; POSTOPERATIVE INFECTION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; SEIZURE; SEPSIS; SIDE EFFECT; SWEATING; TACHYCARDIA; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOSIS; THYMECTOMY; TREATMENT OUTCOME; VEIN THROMBOSIS; VOMITING; WEIGHT GAIN;

EID: 84880107317     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-012-0213-6     Document Type: Article

References (86)

1. Posner JB. Immunology of paraneoplastic syndromes: overview. Ann N Y Acad Sci. 2003;998:178-86.
2. Casetta I, Groppo E, De Gennaro R, et al. Myasthenia gravis: a changing pattern of incidence. J Neurol. 2010;257(12):2015-9.
3. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. 2010;10:46.
4. Andersen JB, Engeland A, Owe JF, Gilhus NE. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. Eur J Neurol. 2010;17(12):1445-50.
5. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475-90. This article provides a clear overview of the immunopathogenesis of myasthenia gravis and its subtypes.
6. Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003;126(10):2304-11.
7. Zhang B, Tzartos JS, Belimezi M, et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol. 2012;69(4):445-51. This studies shows that a proportion of the AChR antibody-negative MG patients have autoantibodies to LRP4 and describes the involvement of these antibodies in the pathogenesis of MG.
8. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol. 2011;69(2):418-22.
9. Marx A, Müller-Hermelink HK, Ströbel P. The role of thymomas in the development of myasthenia gravis. Ann N Y Acad Sci. 2003;998:223-36.
10. Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44(1):36-40. A description of the demographic data, clinical course, response to treatment and long term outcome in a cohort of 110 MuSK-MG patients.
11. Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098-107. A detailed review of the pathogenesis and symptoms of LEMS and clarifying flow charts for the diagnostic work up and treatment of this rare disorder.
12. Gilhus NE. Lambert-eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy. Autoimmune Dis. 2011;973808. doi: 10.4061/2011/973808.
13. Titulaer MJ, Maddison P, Sont JK, et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol. 2011;29(7):902-8.
14. Titulaer MJ, Wirtz PW, Willems LN, et al. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol. 2008;26(26):4276-81.
15. Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011;18(1):19-27.
16. Maddison P. Neuromyotonia. Clin Neurophysiol. 2006;117(10):2118-27.
17. Panagariya A, Kumar H, Mathew V, Sharma B. Neuromyotonia: clinical profile of twenty cases from northwest India. Neurol India. 2006;54(4):382-6.
18. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain. 2010;133(9):2734-48. Interesting study identifying LGI1 and Caspr2 as the major targets of antibodies against the VGKC-complex. The article describes the differences in clinical features and risk of underlying tumour in patients with these antibodies.
19. Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010;9(8):776-85.
20. Lancaster E, Huijbers MG, Bar V, et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol. 2011;69(2):303-11. This study investigates the clinical manifestations and the role of Caspr2 antibodies in neuromyotonia and in encephalitis previously attributed to VGKC-antibodies.
21. Irani SR, Pettingill P, Kleopa KA, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol. 2012;72(2):241-55.
22. Rana SS, Ramanathan RS, Small G, Adamovich B. Paraneoplastic Isaacs' syndrome: a case series and review of the literature. J Clin Neuromuscul Dis. 2012;13(4):228-33.
23. Hart IK, Maddison P, Newsom-Davis J, et al. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain. 2002;125(Pt 8):1887-95.
24. Newsom-Davis J, Buckley C, Clover L, et al. Autoimmune disorders of neuronal potassium channels. Ann N Y Acad Sci. 2003;998:202-10.
25. Mertens HG, Zschocke S. Neuromyotonia. Klin Wochenschr. 1965;43(17):917-25.
26. Vasilescu C, Alexianu M, Dan A. Valproic acid in Isaacs-Mertens syndrome. Clin Neuropharmacol. 1987;10(3):215-24.
27. Maggi L, Mantegazza R. Treatment of myasthenia gravis, focus on pyridostigmine. Clin Drug Investig. 2011;31(10):691-701.
28. Sanders DB, El-Salem K, Massey JM. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003;60(12):1978-80.
29. Hatanaka Y, Hemmi S, Morgan MB, et al. Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG. Neurology. 2005;65(9):1508-9.
30. Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrom (LEMS), clinical and electrodiagnostic features and response to therapy in 59 patients. Ann N Y Acad Sci. 1998;841:823-6.
31. Verschuuren JJGM, Wirtz PW, Titulaer MJ, et al. Available treatment options for the management of Lambert-Eaton myastenic syndrome. Expert Opin Pharmacother. 2006;7(10):1323-36.
32. Wirtz PW, Verschuuren JJ, Van Dijk JG, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther. 2009;86(1):44-8.
33. Beekman R, Kuks JBM, Oosterhuis HJGH. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol. 1997;244(2):112-8.
34. Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myastenic syndrome. Cochrane Database Syst Rev. 2011, 16;(2):CD003279. doi: 10.1002/14651858.CD003279.pub3.
35. McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-diaminopyridine in the treatment of Lambert-Eaton myastenic syndrome. N Engl J Med. 1989;321(23):1567-71.
36. Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology. 2000;54(3):603-7.
37. Oh SJ, Claussen GG, Hatanaka Y, Morgan MB. 3,4-diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve. 2009;40(5):795-800.
38. Wirtz PW, Titulaer MJ, Van Gerven JMA, Verschuuren JJ. 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome. Expert Rev Clin Immunol. 2010;6(6):867-74.
39. Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev. 2005, 18;(2):CD002828. doi: 10.1002/14651858.CD002828.pub2.
40. Pascuzzi RM, Branch Coslett H, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol. 1984;15(3):291-8.
41. Mee J, Paine M, Byrne E, et al. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol. 2003;23(4):251-5.
42. Monsul NT, Patwa HS, Knorr AM, et al. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci. 2004;217(2):131-3.
43. Benatar M, Kaminski HJ. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2007;68(24):2144-9.
44. Kupersmith MJ. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol. 2009;256(8):1314-20.
45. Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2008, (1):CD002277. doi: 10.1002/14651858.CD002277.pub3.
46. Zinman L, Eduardo N, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007;68(11):837-41.
47. Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol. 1997;41(6):789-96.
48. Rønager J, Ravnborg M, Hermansen I, Vorstrup S. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs. 2001;25(12):967-73.
49. Barth D, Nabavi Nouri M, Ng E, et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76(23):2017-23.
50. Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1996;47(3):678-83.
51. Alessi G, De Reuck J, De Bleecker J, Vancayzeele S. Successful immunoglobulin treatment in a patient with neuromyotonia. Clin Neurol Neurosurg. 2000;102(3):173-5.
52. Merchut MP. Management of voltage-gated potassium channel antibody disorders. Neurol Clin. 2010;28(4):941-59.
53. Collongues N, Casez O, Lacour A, et al. Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study. Muscle Nerve. 2012;46(5):687-91.
54. Ibrahim H, Dimachkie MM, Shaibani A. A review: the use of rituximab in neuromuscular diseases. J Clin Neuromuscul Dis. 2010;12(2):91-102.
55. Lebrun C, Bourg V, Tieulie N, Thomas P. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol. 2009;16(2):246-50.
56. Díaz-Manera J, Martínez-Hernández E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology. 2012;78(3):189-93. A follow-up study of the long-term outcome of MG patients treated with rituximab, and a comparison of treatment response in AChR MG and MuSK MG.
57. Maddison P, McConville J, Farrugia ME. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 2011;82(6):671-3.
58. Nowak RJ, Dicapua DB, Zebardast N, Goldstein JM. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord. 2011;4(5):259-66.
59. Blum S, Gillis D, Brown H, et al. Use and monitoring of low dose rituximab in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2011;82(6):659-63.
60. Pellkofer HL, Voltz R, Kuempfel T. Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction. Muscle Nerve. 2009;40(2):305-8.
61. Myasthenia Gravis Clinical Study Group, Gajdos P, Elkharrat D, Chevret S, et al. A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. J Neurol Neurosurg Psychiatry. 1993;56(11):1157-63.
62. Bromberg MB, Wald JJ, Forshew DA. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis. J Neurol Sci. 1997;150(1):59-62.
63. Myasthenia Gravis Study Group, Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology. 1998;50(6):1778-83.
64. Chan JW. Mycophenolate mofetil for ocular myasthenia. J Neurol. 2008;255:510-3.
65. Hehir MK, Burns TM, Alpers J, et al. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve. 2010;41(5):593-8.
66. Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008;71(6):394-9.
67. Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008;71(6):400-6.
68. Tindall RS, Rollins JA, Phillips JT. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med. 1987;316(12):719-24.
69. Tindall RS, Phillips JT, Rollins JA, et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci. 1993;681:539-51.
70. Ponseti JM, Gamez J, Azem J. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann N Y Acad Sci. 2008;1132:254-63.
71. Zhao CB, Zhang X, Zhang H. Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis. Int Immunopharmacol. 2011;11(4):519-24.
72. Nagane Y, Utsugisawa K, Obara D, et al. Efficacy of low-dose FK506 in the treatment of myasthenia gravis-a randomized pilot study. Eur Neurol. 2005;53(3):146-50.
73. Yoshikawa H, Kiuchi T, Saida T, Takamori M. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2011;82(9):970-7.
74. Heckmann JM, Rawoot A, Bateman K, et al. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol. 2011;11:97.
75. Lin PT, Martin BA, Weinacker AB, So YT. High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies. Muscle Nerve. 2006;33(3):433-5.
76. Gladstone DE, Brannagan 3rd TH, Schwartzman RJ, et al. High dose cyclophosphamide for severe refractory myasthenia gravis. J Neurol Neurosurg Psychiatry. 2004;75(5):789-91.
77. De Feo LG, Schottlender J, Martelli NA, Molfino NA. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve. 2002;26(1):31-6.
78. Gajdos P, Simon N, de Rohan-Chabot P, et al. Long-term effects of plasma exchange in myasthenia. Results of a randomized study. Presse Med. 1983;12(15):939-42.
79. Kamel A, Essa M. Effectiveness of prethymecthomy plasmapheresis on short-term outcome of non-thymomatous generalized myasthenia gravis. Egypt J Neurol Psychiatry Neurosurg. 2009;46:161-8.
80. Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology. 1984;34(4):480-5.
81. Sinha S, Newsom-Davis J, Mills K, et al. Autoimmune aetiology for acquired neuromyotonia (Isaacs' syndrome). Lancet. 1991;338(8759):75-7.
82. Hayat GR, Kulkantrakorn K, Campbell WW, Giuliani MJ. Neuromyotonia: autoimmune pathogenesis and response to immune modulating therapy. J Neurol Sci. 2000;181(1-2):38-43.
83. Jaben EA, Winters JL. Plasma exchange as a therapeutic option in patients with neurologic symptoms due to antibodies to voltage-gated potassium channels: a report of five cases and review of the literature. J Clin Apher. 2012;27(5):267-73.
84. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(1):7-15.
85. Guillermo GR, Téllez-Zenteno JF, Weder-Cisneros N, et al. Response of thymectomy: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients. Acta Neurol Scand. 2004;109(3):217-21.
86. Yuan HK, Huang BS, Kung SY, Kao KP. The effectiveness of thymectomy on seronegative generalized myasthenia gravis: comparing with seropositive cases. Acta Neurol Scand. 2007;115(3):181-4.